LINDIS Biotech's Korjuny Approved by European Commission for Malignant Ascites
CompanyDrug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

IASO Bio's Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
CompanyDrug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Innovent Biologics' IBI363 Receives FDA Fast-Track Designation for sqNSCLC
CompanyDrug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Tianyi Medical Acquires Bellco's CRRT Filter Business for EUR11.99m
CompanyDeals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Konruns Pharmaceutical's KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents
CompanyDrug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval
CompanyDrug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing's Departure on BCHT Biotechnology
Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing
Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

AI Transformation in Chinese Medicine: DeepSeek Drives Market Uptick
CompanyDigital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by Proxima Ventures
Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

New Guidelines for Advanced Gastric Cancer Drug Development Released in China
Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Bristol Myers Squibb's Opdualag Fails to Meet Primary Endpoint in Melanoma Study
CompanyDrug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study